-
A temporal perspective for tumor-associated macrophage identities and functions Cancer Cell (IF 50.3) Pub Date : 2024-04-25 Camille Blériot, Garett Dunsmore, Direna Alonso-Curbelo, Florent Ginhoux
Cancer is a progressive disease that can develop and evolve over decades, with inflammation playing a central role at each of its stages, from tumor initiation to metastasis. In this context, macrophages represent well-established bridges reciprocally linking inflammation and cancer via an array of diverse functions that have spurred efforts to classify them into subtypes. Here, we discuss the intertwines
-
Molecular subtypes as potential biomarkers in renal cell carcinoma Cancer Cell (IF 50.3) Pub Date : 2024-04-25 Chadi Hage Chehade, Neeraj Agarwal
The increasing number of approved treatment combinations for metastatic renal cell carcinoma highlights the need for actionable biomarkers to guide treatment selection. In this issue of Cancer Cell, Saliby et al. validate the distinct clinico-genomic profiles of expression-based molecular clusters identified in the IMmotion151 trial in the JAVELIN Renal 101 dataset.
-
Tumor cell-intrinsic epigenetic SETpoint of cancer-associated fibroblasts Cancer Cell (IF 50.3) Pub Date : 2024-04-25 Xiongfeng Chen, Huocong Huang
Cancer-associated fibroblasts (CAFs) exhibit spatial and functional diversity. Here, Niu et al. unveil SETD2’s function in lipid metabolism and CAF heterogeneity in pancreatic ductal adenocarcinoma. SETD2 deficiency boosts oxidative phosphorylation activity, prompting lipid-laden CAF formation through BMP2 signaling, offering promising therapeutic avenues in personalized cancer treatment.
-
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers Cancer Cell (IF 50.3) Pub Date : 2024-04-25 Sarah T. Diepstraten, Yin Yuan, John E. La Marca, Savannah Young, Catherine Chang, Lauren Whelan, Aisling M. Ross, Karla C. Fischer, Giovanna Pomilio, Rhiannon Morris, Angela Georgiou, Veronique Litalien, Fiona C. Brown, Andrew W. Roberts, Andreas Strasser, Andrew H. Wei, Gemma L. Kelly
-
Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization Cancer Cell (IF 50.3) Pub Date : 2024-04-18 Wenying Wang, Tianran Li, Yue Cheng, Fei Li, Shuhong Qi, Min Mao, Jingjing Wu, Qing Liu, Xiaoning Zhang, Xuegang Li, Lu Zhang, Haoyue Qi, Lan Yang, Kaidi Yang, Zhicheng He, Shuaishuai Ding, Zhongyi Qin, Ying Yang, Xi Yang, Chunhua Luo, Yu Shi
-
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia Cancer Cell (IF 50.3) Pub Date : 2024-04-11 Mingyang Liu, Yu Ren, Zhijun Zhou, Jingxuan Yang, Xiuhui Shi, Yang Cai, Alex X. Arreola, Wenyi Luo, Kar-Ming Fung, Chao Xu, Ryan D. Nipp, Michael S. Bronze, Lei Zheng, Yi-Ping Li, Courtney W. Houchen, Yuqing Zhang, Min Li
-
Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer Cancer Cell (IF 50.3) Pub Date : 2024-04-08 Hui Yang, Jinghui Cheng, Hao Zhuang, Hongchuang Xu, Yinuo Wang, Tingting Zhang, Yinmo Yang, Honggang Qian, Yinying Lu, Feng Han, Lihua Cao, Nanmu Yang, Rong Liu, Xing Yang, Jiangong Zhang, Jianmin Wu, Ning Zhang
-
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis Cancer Cell (IF 50.3) Pub Date : 2024-04-08 Darko Barisic, Christopher R. Chin, Cem Meydan, Matt Teater, Ioanna Tsialta, Coraline Mlynarczyk, Amy Chadburn, Xuehai Wang, Margot Sarkozy, Min Xia, Sandra E. Carson, Santo Raggiri, Sonia Debek, Benedikt Pelzer, Ceyda Durmaz, Qing Deng, Priya Lakra, Martin Rivas, Christian Steidl, David W. Scott, Ari Melnick
Abstract not available
-
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia Cancer Cell (IF 50.3) Pub Date : 2024-04-08 Xin Huang, Yizhen Li, Jingliao Zhang, Lei Yan, Huanbin Zhao, Liang Ding, Sheetal Bhatara, Xu Yang, Satoshi Yoshimura, Wenjian Yang, Seth E. Karol, Hiroto Inaba, Charles Mullighan, Mark Litzow, Xiaofan Zhu, Yingchi Zhang, Wendy Stock, Nitin Jain, Elias Jabbour, Steven M. Kornblau, Jun J. Yang
-
Targeting APOBECs in cancer: It’s about timing Cancer Cell (IF 50.3) Pub Date : 2024-04-08 Aaron N. Hata, Mani Larijani
Abstract not available
-
The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions Cancer Cell (IF 50.3) Pub Date : 2024-04-08 Guang Lei, Li Zhuang, Boyi Gan
In cancer treatment, the recurrent challenge of inducing apoptosis through conventional therapeutic modalities, often thwarted by therapy resistance, emphasizes the critical need to explore alternative cell death pathways. Ferroptosis, an iron-dependent form of regulated cell death triggered by the lethal accumulation of lipid peroxides on cellular membranes, has emerged as one such promising frontier
-
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer Cancer Cell (IF 50.3) Pub Date : 2024-04-08 Cai-Jin Lin, Xi Jin, Ding Ma, Chao Chen, Yang Ou-Yang, Yu-Chen Pei, Chao-Zheng Zhou, Fei-Lin Qu, Yun-Jin Wang, Cheng-Lin Liu, Lei Fan, Xin Hu, Zhi-Ming Shao, Yi-Zhou Jiang
-
Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects Cancer Cell (IF 50.3) Pub Date : 2024-04-04 Lukas Kraehenbuehl, Jedd D. Wolchok, Taha Merghoub, Daniel Hirschhorn
Combined immune checkpoint blockade (ICB) for cancer exhibits good efficacy in a subset of patients but also associates with immune-related adverse events. Xue et al. use an elegant drug screening strategy to identify the antimicrobial drug clofazimine as an agent that both potentiates ICB efficacy and decreases immune-related adverse events.
-
Shifting the landscape: The role of IDH inhibitors in glioma cell fate Cancer Cell (IF 50.3) Pub Date : 2024-04-04 Skylar A. Giacobetti, Howard A. Fine
In this issue of Cancer Cell, Spitzer and colleagues demonstrate the role of IDH inhibitors on IDHmutant gliomas in reducing proliferation and enhancing cell differentiation toward an astrocytic-like state, thus altering neurodevelopmental pathways. Despite clinical promise, unresolved questions regarding mechanisms of action and resistance underline the need for further research for treatment optimization
-
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma Cancer Cell (IF 50.3) Pub Date : 2024-04-04 Avishay Spitzer, Simon Gritsch, Masashi Nomura, Alexander Jucht, Jerome Fortin, Ramya Raviram, Hannah R. Weisman, L. Nicolas Gonzalez Castro, Nicholas Druck, Rony Chanoch-Myers, John J.Y. Lee, Ravindra Mylvaganam, Rachel Lee Servis, Jeremy Man Fung, Christine K. Lee, Hiroaki Nagashima, Julie J. Miller, Isabel Arrillaga-Romany, David N. Louis, Hiroaki Wakimoto, Will Pisano, Patrick Y. Wen, Tak W. Mak
-
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes Cancer Cell (IF 50.3) Pub Date : 2024-04-04 Renée Maria Saliby, Chris Labaki, Tejas R. Jammihal, Wanling Xie, Maxine Sun, Valisha Shah, Eddy Saad, M. Harry Kane, Soki Kashima, Katherine Sadak, Talal El Zarif, Deepak Poduval, Robert J. Motzer, Thomas Powles, Brian I. Rini, Laurence Albiges, Sumanta K. Pal, Bradley A. McGregor, Rana R. McKay, Sabina Signoretti, David A. Braun
Abstract not available
-
Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer Cancer Cell (IF 50.3) Pub Date : 2024-04-04 Ningning Niu, Xuqing Shen, Zheng Wang, Yueyue Chen, Yawen Weng, Feier Yu, Yingying Tang, Ping Lu, Mingzhu Liu, Liwei Wang, Yongwei Sun, Minwei Yang, Baiyong Shen, Jiabin Jin, Zipeng Lu, Kuirong Jiang, Yufeng Shi, Jing Xue
-
Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy Cancer Cell (IF 50.3) Pub Date : 2024-03-21 Gang Xue, Xin Li, Muhammad Kalim, Jing Fang, Zhiwu Jiang, Ningbo Zheng, Ziyu Wang, Xiaoyin Li, Maen Abdelrahim, Zhiheng He, Mikhail Nikiforov, Guangxu Jin, Yong Lu
-
Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer Cancer Cell (IF 50.3) Pub Date : 2024-03-21 Pierluigi Di Chiaro, Lucia Nacci, Fabiana Arco, Stefania Brandini, Sara Polletti, Andrea Palamidessi, Benedetta Donati, Chiara Soriani, Francesco Gualdrini, Gianmaria Frigè, Luca Mazzarella, Alessia Ciarrocchi, Alessandro Zerbi, Paola Spaggiari, Giorgio Scita, Simona Rodighiero, Iros Barozzi, Giuseppe R. Diaferia, Gioacchino Natoli
-
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy Cancer Cell (IF 50.3) Pub Date : 2024-03-14 Pedro Berraondo, Gabriel Gomis, Ignacio Melero
mRNA has the potential to encode both vaccines and immunomodulatory proteins for cancer immunotherapy. In this issue, Beck et al. report on lipopolyplexed mRNAs encoding albumin-stabilized interleukin-2 to transduce liver cells. These mRNAs attain antitumor efficacy on subcutaneous mouse tumors even if malignant cells lack major histocompatibility complex class I (MHC class I) expression.
-
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness Cancer Cell (IF 50.3) Pub Date : 2024-03-14 Chun-Pu Lin, Pierre L. Levy, Astrid Alflen, Georgi Apriamashvili, Maarten A. Ligtenberg, David W. Vredevoogd, Onno B. Bleijerveld, Ferhat Alkan, Yuval Malka, Liesbeth Hoekman, Ettai Markovits, Austin George, Joleen J.H. Traets, Oscar Krijgsman, Alex van Vliet, Joanna Poźniak, Carlos Ariel Pulido-Vicuña, Beaunelle de Bruijn, Susan E. van Hal-van Veen, Julia Boshuizen, Daniel S. Peeper
-
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers Cancer Cell (IF 50.3) Pub Date : 2024-03-14 Jan D. Beck, Mustafa Diken, Martin Suchan, Michael Streuber, Elif Diken, Laura Kolb, Lisa Allnoch, Fulvia Vascotto, Daniel Peters, Tim Beißert, Özlem Akilli-Öztürk, Özlem Türeci, Sebastian Kreiter, Mathias Vormehr, Ugur Sahin
-
-
Insights into how adeno-squamous transition drives KRAS inhibitor resistance Cancer Cell (IF 50.3) Pub Date : 2024-03-11 Feng Hu, Piro Lito
-
Improved detection of colibactin-induced mutations by genotoxic E. coli in organoids and colorectal cancer Cancer Cell (IF 50.3) Pub Date : 2024-03-11 Axel Rosendahl Huber, Cayetano Pleguezuelos-Manzano, Jens Puschhof, Joske Ubels, Charelle Boot, Aurelia Saftien, Mark Verheul, Laurianne T. Trabut, Niels Groenen, Markus van Roosmalen, Kyanna S. Ouyang, Henry Wood, Phil Quirke, Gerrit Meijer, Edwin Cuppen, Hans Clevers, Ruben van Boxtel
-
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity Cancer Cell (IF 50.3) Pub Date : 2024-03-11 Miriam Molina-Arcas, Julian Downward
-
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions Cancer Cell (IF 50.3) Pub Date : 2024-03-07 Qing Deng, Priya Lakra, Panhong Gou, Haopeng Yang, Cem Meydan, Matthew Teater, Christopher Chin, Wenchao Zhang, Tommy Dinh, Usama Hussein, Xubin Li, Estela Rojas, Weiguang Liu, Patrick K. Reville, Atish Kizhakeyil, Darko Barisic, Sydney Parsons, Ashley Wilson, Jared Henderson, Brooks Scull, Michael R. Green
-
Unraveling a hidden player in lymphovascular invasion in bladder cancer Cancer Cell (IF 50.3) Pub Date : 2024-03-07 Benjamin Wolf, Rakesh K. Jain
Tumor invasion into the lymphatic vasculature represents a critical step during malignant progression of epithelial cancers. In this issue of Cancer Cell, Zheng et al. unravel how cancer-associated fibroblasts interact with lymphatic endothelial cells and the extracellular matrix to promote lymphatic tumor invasion and suggest that these processes could be treatment targets.
-
SWI/SNF regulation of germinal center fate and lymphomagenesis Cancer Cell (IF 50.3) Pub Date : 2024-03-07 Quinlan Sievers, Omar Abdel-Wahab
The mSWI/SNF subunits ARID1A and SMARCA4 are mutated in B cell lymphomas. Now, Barisic et al. and Deng et al. find that loss of ARID1A or SMARCA4 contributes to lymphomagenesis by causing B cells to aberrantly re-enter germinal centers where they undergo repeated rounds of proliferation and somatic hypermutation.
-
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis Cancer Cell (IF 50.3) Pub Date : 2024-03-07 Darko Barisic, Christopher R. Chin, Cem Meydan, Matt Teater, Ioanna Tsialta, Coraline Mlynarczyk, Amy Chadburn, Xuehai Wang, Margot Sarkozy, Min Xia, Sandra E. Carson, Santo Raggiri, Sonia Debek, Benedikt Pelzer, Ceyda Durmaz, Qing Deng, Priya Lakra, Martin Rivas, Christian Steidl, David W. Scott, Ari Melnick
-
Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Manuel Colucci, Sara Zumerle, Silvia Bressan, Federico Gianfanti, Martina Troiani, Aurora Valdata, Mariantonietta D’Ambrosio, Emiliano Pasquini, Angelica Varesi, Francesca Cogo, Simone Mosole, Cristina Dongilli, Maria Andrea Desbats, Liliana Contu, Ajinkya Revankdar, Jingjing Chen, Madhuri Kalathur, Maria Luna Perciato, Rossella Basilotta, Laczko Endre, Andrea Alimonti
-
Unleashing a safe and potent pro-senescence anti-tumor strategy Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Shasha Chen, Beicheng Sun, Zhongjun Dong
Inducing senescence in tumor cells can stimulate anti-tumor immune responses. In this issue of Cancer Cell, Colucci et al. demonstrate that the combination of the RAR agonist Adapalene with the chemotherapy drug Docetaxel enhances tumor-suppressing senescence and activates an anti-tumor immune response through natural killer cells.
-
PDGFRα+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Hanhao Zheng, Mingjie An, Yuming Luo, Xiayao Diao, Wenlong Zhong, Mingrui Pang, Yan Lin, Jiancheng Chen, Yuanlong Li, Yao Kong, Yue Zhao, Yina Yin, Le Ai, Jian Huang, Changhao Chen, Tianxin Lin
-
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Andrea J. Radtke, Ekaterina Postovalova, Arina Varlamova, Alexander Bagaev, Maria Sorokina, Olga Kudryashova, Mark Meerson, Margarita Polyakova, Ilia Galkin, Viktor Svekolkin, Sergey Isaev, Daniil Wiebe, Anna Sharun, Alexander Sarachakov, Grigory Perelman, Yaroslav Lozinsky, Ziv Yaniv, Bradley C. Lowekamp, Emily Speranza, Li Yao, Stefania Pittaluga, Arthur L. Shaffer III, Danny Jonigk, James D. Phelan
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Dynamic interactions between tumor B cells and the tumor microenvironment (TME) are hypothesized to contribute to the broad
-
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Xinyuan Tong, Ayushi S. Patel, Eejung Kim, Hongjun Li, Yueqing Chen, Shuai Li, Shengwu Liu, Julien Dilly, Kevin S. Kapner, Ningxia Zhang, Yun Xue, Laura Hover, Suman Mukhopadhyay, Fiona Sherman, Khrystyna Myndzar, Priyanka Sahu, Yijun Gao, Fei Li, Fuming Li, Zhaoyuan Fang, Yujuan Jin, Juntao Gao, Minglei Shi, Satrajit Sinha, Luonan Chen, Yang Chen, Thian Kheoh, Wenjing Yang, Itai Yanai, Andre L. Moreira
KRAS inhibitors (adagrasib and sotorasib) have shown clinical promise in targeting -mutated lung cancers; however, most patients eventually develop resistance. In lung patients with adenocarcinoma with and / co-mutations, we find an enrichment of the squamous cell carcinoma gene signature in pre-treatment biopsies correlates with a poor response to adagrasib. Studies of -deficient and lung cancer mouse
-
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Xue-Yan He, Yuan Gao, David Ng, Evdokia Michalopoulou, Shanu George, Jose M. Adrover, Lijuan Sun, Jean Albrengues, Juliane Daßler-Plenker, Xiao Han, Ledong Wan, Xiaoli Sky Wu, Longling S. Shui, Yu-Han Huang, Bodu Liu, Chang Su, David L. Spector, Christopher R. Vakoc, Linda Van Aelst, Mikala Egeblad
Chronic stress is associated with increased risk of metastasis and poor survival in cancer patients, yet the reasons are unclear. We show that chronic stress increases lung metastasis from disseminated cancer cells 2- to 4-fold in mice. Chronic stress significantly alters the lung microenvironment, with fibronectin accumulation, reduced T cell infiltration, and increased neutrophil infiltration. Depleting
-
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Michael Dennis, Robert Haddad
-
Characterization of the generic mutant p53-rescue compounds in a broad range of assays Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Shujun Xiao, Fangfang Shi, Huaxin Song, Jingyi Cui, Derun Zheng, Hesong Zhang, Kai Tan, Jiaqi Wu, Xueqin Chen, Jiale Wu, Yigang Tang, Yuting Dai, Min Lu
-
Vascular characterization reveals immunomodulatory targets for brain metastases Cancer Cell (IF 50.3) Pub Date : 2024-02-15 Roberta Lugano, Anna Dimberg
-
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade Cancer Cell (IF 50.3) Pub Date : 2024-02-15 Barzin Y. Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M. Elhossiny, Minu K. Srivastava, Namrata S. Patil, Kiandra A. Smith, Rajiv Jesudason, Caleb Chan, Patrick S. Chang, Matthew Fernandez, Sandra Rost, Lisa M. McGinnis, Hartmut Koeppen, Carl M. Gay, John D. Minna, John V. Heymach, Joseph M. Chan, Charles M. Rudin, Lauren A. Byers,
Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer understanding of therapeutically relevant SCLC subsets could identify rational combination strategies and improve outcomes. We conduct transcriptomic analyses and non-negative matrix factorization on 271 pre-treatment patient tumor samples
-
Re-inventing a better wheel? Serplulimab for squamous cell lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Derek De-Rui Huang, James Chih-Hsin Yang
-
Envision the future of precision medicine in pediatric cancer Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Y, ., A, ., , D, e, C, l, e, r, c, k
-
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Ning-Ning Liu, Cheng-Xiang Yi, Lu-Qi Wei, Jin-An Zhou, Tong Jiang, Cong-Cong Hu, Lu Wang, Yuan-Yuan Wang, Yun Zou, Yi-Kai Zhao, Le-Le Zhang, Ya-Ting Nie, Yi-Jing Zhu, Xin-Yao Yi, Ling-Bing Zeng, Jing-Quan Li, Xiao-Tian Huang, Hong-Bin Ji, Zisis Kozlakidis, Lin Zhong, Christopher Heeschen, Xiao-Qi Zheng, Changbin Chen, Peng Zhang, Hui Wang
-
Precision treatment in advanced hepatocellular carcinoma Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Xupeng Yang, Chen Yang, Shu Zhang, Haigang Geng, Andrew X. Zhu, René Bernards, Wenxin Qin, Jia Fan, Cun Wang, Qiang Gao
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision treatment represents a paradigm shift in cancer treatment in recent years. This approach utilizes the
-
Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Michael S. Samuel, Jose I. Lopez, Ewan J. McGhee, Daniel R. Croft, David Strachan, Paul Timpson, June Munro, Ewald Schröder, Jing Zhou, Valerie G. Brunton, Nick Barker, Hans Clevers, Owen J. Sansom, Kurt I. Anderson, Valerie M. Weaver, Michael F. Olson
-
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Elias Bou Farhat, Elio Adib, Melissa Daou, Abdul Rafeh Naqash, Ursula Matulonis, Kimmie Ng, David J. Kwiatkowski, Lynette M. Sholl, Amin H. Nassar
-
Inosine induces stemness features in CAR-T cells and enhances potency Cancer Cell (IF 50.3) Pub Date : 2024-01-25 Dorota D. Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A. Freitas, Yiyun Chen, Stefanie Meier, Bence Daniel, Katalin Sandor, Peng Xu, Jing Huang, Louai Labanieh, Vimal Keerthi, Amaury Leruste, Malek Bashti, Janette Mata-Alcazar, Nikolaos Gkitsas, Justin A. Guerrero, Chris Fisher, Sunny Patel, Kyle Asano, Shabnum Patel, Kara L. Davis, Ansuman T. Satpathy, Steven A. Feldman, Elena
-
Unlocking CAR T cell potential: Inosine-induced stemness and enhanced potency Cancer Cell (IF 50.3) Pub Date : 2024-01-25 Xingying Zhang, Haoyi Wang
Adenosine (Ado) drives immune suppression in the tumor microenvironment. In this issue of Cancer Cell, Klysz et al. investigate Ado-mediated immunosuppression. Overexpression of Ado deaminase (ADA-OE), metabolizing Ado to inosine (INO), induces stemness and improves CAR T cell functionality. Likewise, exposure to INO enhances CAR T cells’ function and induces stemness features.
-
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes Cancer Cell (IF 50.3) Pub Date : 2024-01-25 Simon Heeke, Carl M. Gay, Marcos R. Estecio, Hai Tran, Benjamin B. Morris, Bingnan Zhang, Ximing Tang, Maria Gabriela Raso, Pedro Rocha, Siqi Lai, Edurne Arriola, Paul Hofman, Veronique Hofman, Prasad Kopparapu, Christine M. Lovly, Kyle Concannon, Luana Guimaraes De Sousa, Whitney Elisabeth Lewis, Kimie Kondo, Xin Hu, Azusa Tanimoto, Natalie I. Vokes, Monique B. Nilsson, Allison Stewart, Maarten Jansen
-
Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms Cancer Cell (IF 50.3) Pub Date : 2024-01-18 Leire Bejarano, Annamaria Kauzlaric, Eleni Lamprou, Joao Lourenco, Nadine Fournier, Michelle Ballabio, Roberto Colotti, Roeltje Maas, Sabine Galland, Matteo Massara, Klara Soukup, Johanna Lilja, Jean-Philippe Brouland, Andreas F. Hottinger, Roy T. Daniel, Monika E. Hegi, Johanna A. Joyce
-
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-01-18 Lena Cords, Stefanie Engler, Martina Haberecker, Jan Hendrik Rüschoff, Holger Moch, Natalie de Souza, Bernd Bodenmiller
-
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma Cancer Cell (IF 50.3) Pub Date : 2024-01-18 Xiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, Ya-Qian Han, Feng Lei, Liang-Fang Shen, Kun-Yu Yang, Lei Chen, Yan-Ping Mao, Ling-Long Tang, Ling Li, Zheng Wu, Gui-Qiong Xu, Qin Zhou, Jing Huang, Rui Guo, Yuan Zhang, Xu Liu, Guan-Qun Zhou, Wen-Fei Li, Cheng Xu, Li Lin, Yu-Pei Chen, Fo-Ping Chen, Xiao-Yu Liang, Si-Yuan Chen, Shu-Qi Li, Chun-Yan Cui, Ji-Bin Li, Jian Ren, Ming-Yuan Chen, Li-Zhi Liu, Ying
-
Integrated proteogenomic characterization of glioblastoma evolution Cancer Cell (IF 50.3) Pub Date : 2024-01-11 Kyung-Hee Kim, Simona Migliozzi, Harim Koo, Jun-Hee Hong, Seung Min Park, Sooheon Kim, Hyung Joon Kwon, Seokjun Ha, Luciano Garofano, Young Taek Oh, Fulvio D'Angelo, Chan Il Kim, Seongsoo Kim, Ji Yoon Lee, Jiwon Kim, Jisoo Hong, Eun-Hae Jang, Bertrand Mathon, Anna-Luisa Di Stefano, Franck Bielle, Alice Laurenge, Alexey I. Nesvizhskii, Eun-Mi Hur, Jinlong Yin, Bingyang Shi, Youngwook Kim, Kyung-Sub
-
A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization Cancer Cell (IF 50.3) Pub Date : 2024-01-11 Clare Pacini, Emma Duncan, Emanuel Gonçalves, James Gilbert, Shriram Bhosle, Stuart Horswell, Emre Karakoc, Howard Lightfoot, Ed Curry, Francesc Muyas, Monsif Bouaboula, Chandra Sekhar Pedamallu, Isidro Cortes-Ciriano, Fiona M. Behan, Lykourgos-Panagiotis Zalmas, Andrew Barthorpe, Hayley Francies, Steve Rowley, Jack Pollard, Pedro Beltrao, Leopold Parts, Francesco Iorio, Mathew J. Garnett
-
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-01-11 Danish Memon, Adam J. Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi Miriyala, Jennifer L. Sauter, Jia Luo, Andrew Chow, Umesh K. Bhanot, Caroline McCarthy, Chad M. Vanderbilt, Cailian Liu, Mohsen Abu-Akeel, Andrew J. Plodkowski, Nicholas McGranahan, Marta Łuksza, Benjamin D. Greenbaum, Taha Merghoub
-
Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy Cancer Cell (IF 50.3) Pub Date : 2024-01-11 James D. Phelan, Sebastian Scheich, Jaewoo Choi, George W. Wright, Björn Häupl, Ryan M. Young, Sara A. Rieke, Martine Pape, Yanlong Ji, Henning Urlaub, Arnold Bolomsky, Carmen Doebele, Alena Zindel, Tanja Wotapek, Monica Kasbekar, Brett Collinge, Da Wei Huang, Zana A. Coulibaly, Vivian M. Morris, Xiaoxuan Zhuang, Julius C. Enssle, Xin Yu, Weihong Xu, Yandan Yang, Hong Zhao, Zhuo Wang, Andy D. Tran
-
Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon? Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Simona F. Shaitelman, Wendy A. Woodward
Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.
-
Immune evasion by dormant disseminated cancer cells: A Fermi paradox? Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Anna Adam-Artigues, Luis E. Valencia Salazar, Julio A. Aguirre-Ghiso
Rare disseminated tumor cells (DTCs) can persist after treatment in patients for years, and the immune system does not eliminate them. Goddard et al. propose that immune evasion by rare dormant DTCs is due to an improbability of contact imposed by large distances separating effector T cells and DTCs.
-
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Stephen L. Shiao, Kenneth H. Gouin III, Nathan Ing, Alice Ho, Reva Basho, Aagam Shah, Richard H. Mebane, David Zitser, Andrew Martinez, Natalie-Ya Mevises, Bassem Ben-Cheikh, Regina Henson, Monica Mita, Philomena McAndrew, Scott Karlan, Armando Giuliano, Alice Chung, Farin Amersi, Catherine Dang, Heather Richardson, Wonwoo Shon, Farnaz Dadmanesh, Michele Burnison, Amin Mirhadi, Zachary S. Zumsteg,
Strategies are needed to better identify patients that will benefit from immunotherapy alone or who may require additional therapies like chemotherapy or radiotherapy to overcome resistance. Here we employ single-cell transcriptomics and spatial proteomics to profile triple negative breast cancer biopsies taken at baseline, after one cycle of pembrolizumab, and after a second cycle of pembrolizumab
-
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Erica T. Goddard, Miles H. Linde, Shivani Srivastava, Grant Klug, Tamer B. Shabaneh, Santino Iannone, Candice A. Grzelak, Sydney Marsh, Alessandra I. Riggio, Ryann E. Shor, Ian L. Linde, Marissa Guerrero, Joshua R. Veatch, Annelise G. Snyder, Alana L. Welm, Stanley R. Riddell, Cyrus M. Ghajar